If no myostatin inhibition treatment has been able to improve severe (DMD), intermediate (sIBM), moderate (LGMD) muscle disorders or muscle wasting related to cancer or age, then this mode of treatment is likely not suited for treating any of these disorders and conditions. The gene discussed is MSTN; the disease is Duchenne muscular dystrophy.